Patents by Inventor Renfeng Guo

Renfeng Guo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of inflammatory diseases with inhibitors of C5A activity
    Patent number: 11890349
    Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: February 6, 2024
    Assignee: InflaRx GmbH
    Inventors: Renfeng Guo, Niels C. Riedemann
  • HUMANIZED ANTI-C5A ANTIBODIES
    Publication number: 20230279087
    Abstract: The present invention relates to antibodies that specifically bind to a conformational epitope of human C5a. The invention particularly relates to humanized anti-C5a antibodies. The antibodies described herein are useful as active agents in pharmaceutical compositions. The antibodies and pharmaceutical compositions are especially useful for the treatment and prevention of diseases or disorders involving pathological C5a activity.
    Type: Application
    Filed: May 6, 2021
    Publication date: September 7, 2023
    Applicant: InflaRx GmbH
    Inventors: Renfeng GUO, Niels C. RIEDEMANN
  • Inhibitors of C5a for the Treatment of Corona Virus Infection
    Publication number: 20230158060
    Abstract: The present invention relates to an inhibitor of C5a activity medical condition caused by or associated with infection with a corona virus. The invention also relates to the use of an inhibitor of C5a activity in the reduction of an inflammatory response in a subject suffering from a corona virus infection. The invention further relates to an inhibitor of C5a activity for use in the improvement of organ function, in particular lung function and/or hepatic function, in a subject suffering from a corona virus infection.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 25, 2023
    Applicant: InflaRx GmbH
    Inventors: Niels C. RIEDEMANN, Renfeng GUO
  • Treatment of inflammatory diseases with inhibitors of C5A activity
    Patent number: 11464868
    Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: October 11, 2022
    Assignee: InflaRx GmbH
    Inventors: Renfeng Guo, Niels C. Riedemann
  • Treatment of inflammatory diseases with inhibitors of C5a activity
    Patent number: 11273225
    Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: March 15, 2022
    Assignee: InflaRx GmbH
    Inventors: Renfeng Guo, Niels R. Riedemann
  • FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR
    Publication number: 20210403433
    Abstract: The present invention relates to fused piperidinyl bicyclic, meta-substituted piperidinyl and their related compounds that modulate activities of mammalian C5a receptor by directly binding to the C5a receptor. The invention also relates to pharmaceutical compositions containing such compounds and their use in the treatment of a disease or a disorder involving pathogenic activation of C5a receptors.
    Type: Application
    Filed: September 9, 2021
    Publication date: December 30, 2021
    Applicant: InflaRx GmbH
    Inventors: YONG LI, RENFENG GUO, NIELS CHRISTOPH RIEDEMANN
  • Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor
    Patent number: 11149009
    Abstract: The present invention relates to fused piperidinyl bicyclic, meta-substituted piperidinyl and their related compounds that modulate activities of mammalian C5a receptor by directly binding to the C5a receptor. The invention also relates to pharmaceutical compositions containing such compounds and their use in the treatment of a disease or a disorder involving pathogenic activation of C5a receptors.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: October 19, 2021
    Assignee: InflaRx GmbH
    Inventors: Yong Li, Renfeng Guo, Niels Christoph Riedemann
  • TREATMENT OF INFLAMMATORY DISEASES WITH INHIBITORS OF C5A ACTIVITY
    Publication number: 20210046191
    Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
    Type: Application
    Filed: November 2, 2020
    Publication date: February 18, 2021
    Applicant: InflaRx GmbH
    Inventors: Renfeng Guo, Niels C. Riedemann
  • Inhibitors of C5A for the treatment of viral pneumonia
    Patent number: 10858421
    Abstract: The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The inventors further relates to methods for the treatment of pneumonia, especially viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: December 8, 2020
    Assignee: INFLARX GMBH
    Inventors: Renfeng Guo, Niels Christoph Riedemann
  • FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR
    Publication number: 20200290969
    Abstract: The present invention relates to fused piperidinyl bicyclic, meta-substituted piperidinyl and their related compounds that modulate activities of mammalian C5a receptor by directly binding to the C5a receptor. The invention also relates to pharmaceutical compositions containing such compounds and their use in the treatment of a disease or a disorder involving pathogenic activation of C5a receptors.
    Type: Application
    Filed: February 7, 2020
    Publication date: September 17, 2020
    Applicant: InflaRx GmbH
    Inventors: YONG LI, RENFENG GUO, NIELS CHRISTOPH RIEDEMANN
  • Anti-C5a binding moieties with high blocking activity
    Patent number: 10774136
    Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 15, 2020
    Assignee: INFLARX GMBH
    Inventors: Renfeng Guo, Niels Christoph Riedemann, Yan Li, Beifen Shen
  • TREATMENT OF INFLAMMATORY DISEASES WITH INHIBITORS OF C5A ACTIVITY
    Publication number: 20200061202
    Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
    Type: Application
    Filed: August 7, 2019
    Publication date: February 27, 2020
    Applicant: InflaRx GmbH
    Inventors: Renfeng Guo, Niels C. Riedemann
  • Treatment of inflammatory diseases with inhibitors of C5a activity
    Patent number: 10376595
    Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: August 13, 2019
    Assignee: InflaRx GmbH
    Inventors: Renfeng Guo, Niels C. Riedemann
  • INHIBITORS OF C5A FOR THE TREATMENT OF VIRAL PNEUMONIA
    Publication number: 20190202900
    Abstract: The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The inventors further relates to methods for the treatment of pneumonia, especially viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof.
    Type: Application
    Filed: January 24, 2019
    Publication date: July 4, 2019
    Inventors: Renfeng GUO, Niels Christoph RIEDEMANN
  • Inhibitors of C5a for the treatment of viral pneumonia
    Patent number: 10227397
    Abstract: The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The inventors further relates to methods for the treatment of pneumonia, especially viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: March 12, 2019
    Assignee: INFLARX GMBH
    Inventors: Renfeng Guo, Niels Christoph Riedemann
  • TREATMENT OF INFLAMMATORY DISEASES WITH INHIBITORS OF C5A ACTIVITY
    Publication number: 20180282425
    Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 4, 2018
    Applicant: InflaRx GmbH
    Inventors: Renfeng Guo, Niels R. Riedemann
  • TREATMENT OF INFLAMMATORY DISEASES WITH INHIBITORS OF C5A ACTIVITY
    Publication number: 20180280530
    Abstract: The present invention relates to inhibitors of C5a activity and their use in the treatment of cutaneous, neutrophilic, inflammatory diseases in a subject.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 4, 2018
    Applicant: InflaRx GmbH
    Inventors: Renfeng Guo, Niels R. Riedemann
  • INHIBITORS OF C5A FOR THE TREATMENT OF VIRAL PNEUMONIA
    Publication number: 20170137499
    Abstract: The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The inventors further relates to methods for the treatment of pneumonia, especially viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof.
    Type: Application
    Filed: March 20, 2015
    Publication date: May 18, 2017
    Applicant: INFLARX GMBH
    Inventors: Renfeng GUO, Niels Christoph RIEDEMANN
  • Anti-C5a Binding Moieties With High Blocking Activity
    Publication number: 20170002067
    Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.
    Type: Application
    Filed: September 16, 2016
    Publication date: January 5, 2017
    Inventors: Renfeng GUO, Niels Christoph RIEDEMANN, Yan LI, Beifen SHEN
  • Anti-C5a binding moieties with high blocking activity
    Patent number: 9458233
    Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: October 4, 2016
    Assignee: INFLARX GMBH
    Inventors: Renfeng Guo, Niels Christoph Riedemann, Yan Li, Beifen Shen